An Open, Prospective Study to Assess the Efficacy and Safety of FK506 Combined MMF in the Treatment of Class III, IV, V + IV or V + III Lupus Nephritis.

Trial Profile

An Open, Prospective Study to Assess the Efficacy and Safety of FK506 Combined MMF in the Treatment of Class III, IV, V + IV or V + III Lupus Nephritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Tacrolimus (Primary) ; Cyclophosphamide; Mycophenolate mofetil
  • Indications Lupus nephritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 May 2010 Actual patient number (120) added as reported by ClinicalTrials.gov.
    • 25 May 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top